1. Interim Analysis of a 3-Year Follow-up Study of NS5A and NS3 Resistance-Associated Variants After Treatment With Grazoprevir-Containing Regimens in Patients With Chronic Hepatitis C Virus (HCV) Infection

2. Disclosures

3. Acknowledgements

4. background

5. Background

6. Methods

7. Grazoprevir treatment regimens

8. Patient Demographics

9. Patients with GT1 NS3 RAVs Detected at the time of failure

10. Patients with GT1 NS3 RAVs Detected at the time of failure

11. Patients with GT1 NS5A RAVs Detected at the time of failure

12. Patients with GT1 NS5A RAVs Detected at the time of failure

13. Pre-existing NS3 and NS5A RAVs Persist >2 years post-treatment

14. Persistence of Treatment-emergent RAVs varies by target Region

15. The Profile of Pre-existing NS3 and NS5A RAVs is similar at virologic failure and at FW48

16. NS3 But noT NS5A Treatment-emergent RAVs show reversion to WT between virologic failure and FW48

17. Persistence of individual treatment-emergent ravs

18. Summary